Welcome to Inorbit Therapeutics AB
Inorbit Therapeutics AB discovers and develops small molecule therapeutics based on molecules with proven clinical efficacy in humans. Inorbit focuses currently on compounds for the treatment of Type 2 Diabetes Mellitus, Gout, Fatty Liver Disease (NAFLD / NASH), and inflammatory diseases. Inorbit scouts for marketed drugs and for drugs that failed in late stages of drug development, which are characterized by high lipophilicity and risk for (idiosyncratic) liver failure. After establishing the freedom to operate and patentability, Inorbit applies its novel chemistry to these molecules to reduce toxicity and enhance efficacy. By applying its chemistry to molecules with documented human efficacy, Inorbit reduces discovery and development time and expense, minimizes risk, and quickly creates shareholder value from a minimal initial investment.